Skip to main content

EGFR Exon 20 Insertion Mutation clinical trials at UC Health
2 research studies open to eligible people

  • EGFR Inhibitor AZD9291 (Osimertinib) and Monoclonal antibodies (Necitumumab) side effects and best dosing for Lung Cancer

    “This study looks at experimental immunotherapy combination: necitumumab and osimertinib in treating Stage IV or Recurrent lung cancer”

    open to eligible people ages 18 years and up

    This phase I trial studies the side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a better treatment for EGFR-mutant non-small cell lung cancer.

    at UC Davis

  • Phase 2 Study of Tarloxotinib in Patients With NSCLC Harboring EGFR Exon 20 Insertion or HER2-activating Mutations

    open to eligible people ages 18 years and up

    Open-label, Phase 2, single treatment arm, 2 cohorts

    at UC Irvine

Last updated: